Fisoa

Phyllanthus amarus contains hepatoprotective lignans (phyllanthin, hypophyllanthin), tannins (geraniin, corilagin), and flavonoids (quercetin, rutin) that inhibit NF-κB signaling, downregulate TNF-α and IL-1β, and block CCl4-induced hepatic oxidative stress and fibrosis via caspase-3-mediated pathways. Preclinical evidence demonstrates that the lignan phyllanthin suppresses hepatic fibrosis markers and that chicken liver enzyme studies confirmed no hepatotoxicity at doses of 250–1,000 mg/mL over 14 days, though no human randomized controlled trials have yet confirmed these hepatoprotective effects.

Origin & History

Phyllanthus amarus is a small annual herb native to tropical and subtropical regions, including the Pacific Islands, South Asia, West Africa, and the Americas, where it thrives in disturbed soils, roadsides, and cultivated fields up to 1,000 meters elevation. In Samoa and broader Polynesia, it grows as a common weed and is harvested from wild populations rather than cultivated. The plant prefers warm, humid climates with well-drained soils and reaches 10–60 cm in height, producing small, oblong leaves arranged in two rows along slender branches.

Historical & Cultural Context

In Samoan traditional medicine, Fisoa (Phyllanthus amarus) holds an established role as a remedy for liver disorders, with healers administering leaf decoctions to address jaundice and general hepatic weakness, reflecting a broader Pacific Islander pharmacopoeia that emphasizes plant-based hepatic tonics. Across South and Southeast Asia, the plant — known variously as bhumyamalaki in Ayurveda and Stone Breaker in Caribbean herbal tradition — has been employed for millennia to treat kidney stones, viral hepatitis, and urinary infections, appearing in classical Ayurvedic texts such as the Charaka Samhita. In West African ethnomedicine, whole-plant preparations are used for malaria, gonorrhea, and hypertension, demonstrating the broad geographic reach of its traditional applications. The consistency of hepatoprotective use across culturally distinct populations — Polynesian, South Asian, African, and Amazonian — represents a striking example of ethnopharmacological convergence that has motivated modern phytochemical investigation.

Health Benefits

- **Hepatoprotection**: Phyllanthin and hypophyllanthin suppress CCl4-induced hepatic oxidative stress and fibrosis; in vitro data show induction of HepG2 apoptosis via caspase-3, and animal studies confirm preservation of normal ALT/AST/ALP ranges.
- **Anti-inflammatory Activity**: Ethanolic and aqueous extracts inhibit TNF-α, IL-1β, PGE2, and COX-2 expression, and downregulate NF-κB, TLR4, and MyD88 signaling cascades in LPS-stimulated macrophage models.
- **Antioxidant Defense**: DPPH radical scavenging activity reaches up to 74.4% inhibition, attributed to phenolic compounds including geraniin, corilagin, quercetin, and rutin, which quench reactive oxygen species and protect cellular membranes.
- **Antimicrobial and Antiparasitic Effects**: Aqueous and ethanolic leaf extracts demonstrate activity against bacterial pathogens and reduce trypanosomal parasitaemia in rodent models, mediated by tannins and alkaloids disrupting pathogen membrane integrity.
- **Antihypertensive Potential**: Aqueous extracts have been shown in rodent studies to lower blood pressure, likely through modulation of smooth muscle tone and prostaglandin biosynthesis via fatty acid constituents including palmitic acid and phytol.
- **Anticancer/Cytotoxic Signaling**: Phyllanthin triggers apoptosis in HepG2 liver cancer cells via caspase-3 activation and modulation of Akt and MAPK (JNK, ERK, p38) pathways, suggesting potential adjunctive oncological relevance pending clinical investigation.
- **Immunomodulation**: Downregulation of NF-κB, MyD88, and TLR4 in macrophage models indicates broad immunomodulatory capacity that may help temper excessive inflammatory responses associated with chronic liver disease and infection.

How It Works

The hepatoprotective lignan phyllanthin blocks CCl4-induced lipid peroxidation and oxidative hepatocyte damage by quenching reactive oxygen species and preserving mitochondrial membrane integrity, while simultaneously inducing apoptosis in aberrant hepatocytes via caspase-3 activation. Anti-inflammatory activity is driven by downregulation of the NF-κB/TLR4/MyD88 signaling axis, resulting in reduced transcription of COX-2, TNF-α, IL-1β, and PGE2 in macrophages exposed to lipopolysaccharide. Tannins such as geraniin and corilagin contribute antioxidant effects through direct radical scavenging (DPPH IC50 consistent with up to 74.4% inhibition) and chelation of redox-active metal ions, while flavonoids quercetin and rutin modulate MAPK pathways (JNK, ERK, p38) to attenuate inflammatory gene expression. Additionally, the plant inhibits intestinal and hepatic CYP3A4 enzyme activity, substantially altering the pharmacokinetics of co-administered CYP3A substrates such as midazolam, increasing their systemic exposure by as much as 9.6-fold in AUC.

Scientific Research

Research on Phyllanthus amarus is predominantly preclinical, consisting of in vitro cell culture experiments and small animal studies, with no published human randomized controlled trials identified in the current literature base. Animal studies include rodent models demonstrating reduced trypanosomal parasitaemia with ethanol extract and antihypertensive effects with aqueous extract, and a poultry hepatotoxicity study at 250–1,000 mg/mL over 14 days confirming normal hepatic enzyme profiles (AST approximately 33–56 IU/L). A pharmacokinetic interaction study identified a 3.9-fold increase in midazolam Cmax and 9.6-fold increase in AUC following co-administration, pointing to clinically significant CYP3A inhibition. The overall evidence base is characterized by methodological heterogeneity, small or unspecified sample sizes, and absence of Phase I–III human trials, meaning all hepatoprotective and anti-inflammatory claims remain unconfirmed in humans.

Clinical Summary

No human clinical trials evaluating Fisoa (Phyllanthus amarus) for liver disease or any other indication have been identified in the peer-reviewed literature at this time. The most quantitatively informative preclinical data derive from a 14-day poultry study using n-hexane extracts at 250–1,000 mg/mL, which documented stable hepatic enzyme markers (ALT, AST, ALP, total protein) without significant deviation from control values, suggesting low acute hepatotoxicity in that model. A pharmacokinetic study documenting CYP3A inhibition — with midazolam AUC increasing 9.6-fold and clearance reduced by 12% — represents the most clinically actionable finding, carrying direct implications for drug interaction risk. Confidence in therapeutic efficacy for liver conditions in humans is low pending adequately powered, placebo-controlled clinical trials.

Nutritional Profile

Phyllanthus amarus leaves contain a complex matrix of bioactive phytochemicals rather than significant macronutrient content. Key lignans include phyllanthin and hypophyllanthin (concentrations vary by extraction but are detectable by LC-MS/MS), and tannins geraniin, amariin, and corilagin are among the dominant polyphenols. Flavonoids quercetin and rutin contribute to the antioxidant phenolic pool, while the terpenes lupeol and oleanolic acid represent the principal triterpene fraction. Fatty acid profiling of ethanolic extracts identifies palmitic acid (11.8%), dioctyl ester (10.1%), 9-hexadecenal (9.0%), and 2,13-octadecadiene-1-ol (8.2%) as major constituents by relative percentage. The lipophilic fraction includes phytol and vitamin E (tocopherol), and alkaloid content contributes to the plant's antimicrobial properties. Bioavailability of polyphenolic compounds is enhanced by 80% ethanolic extraction relative to aqueous preparations, likely due to increased solubility of lignans and lipid-soluble terpenes.

Preparation & Dosage

- **Traditional Samoan Decoction**: Fresh or dried leaves (approximately 5–10 g) boiled in water and consumed as a tea; preparation method mirrors use across Pacific Islander and South Asian traditions for liver and urinary complaints.
- **Aqueous Extract (Tea/Infusion)**: Whole dried herb steeped in hot water; no standardized human dose established; used empirically in traditional settings.
- **Ethanolic Leaf Extract**: Research preparations employ 70–80% ethanol extractions; animal studies used 250–1,000 mg/mL concentrations, which are not directly translatable to human supplemental doses.
- **n-Hexane Extract**: Used in phytochemical and toxicity research at 250–1,000 mg/mL; not a form typically available as a consumer supplement.
- **Standardized Supplements**: No internationally recognized standardization percentage for phyllanthin or hypophyllanthin content exists; products claiming standardization should be evaluated with caution.
- **Timing**: Traditional use involves consumption 1–2 times daily with meals; no evidence-based timing guidance for supplemental use is available.
- **Dose Caution**: No safe or effective human dose range has been established through clinical trials; caution is warranted especially in individuals taking CYP3A4-metabolized medications.

Synergy & Pairings

Phyllanthus amarus is traditionally combined with other hepatoprotective herbs such as Andrographis paniculata and Boerhavia diffusa in Ayurvedic formulations (e.g., Liv-52 analogues), where additive NF-κB suppression and complementary antioxidant mechanisms may amplify hepatoprotective outcomes beyond individual herb effects. The quercetin and rutin content of Phyllanthus amarus may exhibit synergy with phosphatidylcholine (lecithin), which enhances polyphenol bioavailability by forming phytosome complexes that improve intestinal absorption. Pairing with silymarin (milk thistle) is a rationally supported combination, as silymarin's flavonolignans and phyllanthin operate via overlapping but distinct hepatoprotective mechanisms — membrane stabilization and antifibrotic signaling respectively — that together may offer broader hepatic coverage.

Safety & Interactions

Phyllanthus amarus has demonstrated an absence of acute hepatotoxicity in poultry studies at doses of 250–1,000 mg/mL over 14 days, with liver enzyme markers remaining within normal ranges, and no toxicity has been reported in Drosophila models, supporting a generally favorable acute safety profile in non-human models. The most critical safety concern is potent inhibition of CYP3A4, which increases systemic exposure of CYP3A substrates — including midazolam, statins, calcineurin inhibitors, and certain antiretrovirals — by up to 9.6-fold in AUC, representing a clinically significant drug interaction risk that warrants avoidance in polypharmacy contexts. No formal contraindications have been established, but use during pregnancy and lactation cannot be considered safe given the complete absence of human safety data and the presence of biologically active alkaloids and tannins that may affect uterine tone or neonatal hepatic enzyme maturation. Maximum safe human doses have not been determined through clinical research, and individuals with pre-existing liver disease, renal impairment, or those taking narrow-therapeutic-index medications should seek physician guidance before use.